Catabasis Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: CATB |
| Industry | Pharmaceuticals |
| Headquarters | Cambridge, Massachusetts |
Key people |
Jill C. Milne, Ph.D. (CEO) Joanne M. Donovan, M.D., Ph.D. (Chief Medical Officer and Senior Vice President, Clinical Development) Ted Hibben (Chief Business Officer) Andrew Nichols, Ph.D. (Chief Scientific Officer) |
| Products | Orally-delivered pharmaceuticals |
Number of employees | 34 (June 2015) |
| Website | www.catabasis.com |
Catabasis Pharmaceuticals, founded in 2008 and based in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company.[1] Catabasis’ SMART (Safely Metabolized And Rationally Targeted) linker drug discovery platform enables the company to engineer molecules that simultaneously modulate multiple targets in a disease.[2] Catabasis is applying their SMART linker platform to build an internal pipeline of product candidates for rare diseases and plans to pursue partnerships to develop additional product candidates.
References
- ↑ "Our Story - Our Company - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
- ↑ "Our Technology - Our Technology & Pipeline - Catabasis". www.catabasis.com. Retrieved 2017-02-17.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.